SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Google

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Antivirals may help monkeypox patients
Wed May 25th - Antiviral medications may be effective against monkeypox, researchers have found, but more research is urgently needed. More
Anti-ageing drugs prevent radiotherapy impact
Wed May 25th - The long-term impact of radiation therapy for cancer could be limited with a class of drugs called senolytics, researchers say. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Chinese COVID-19 vaccine is effective against severe disease

Friday December 24th 2021

One dose of the Ad5-nCoV COVID-19 vaccine is 57.5% effective against symptomatic infection and 91.7% effective against severe disease after 28 days of vaccination, researchers report today.

A phase 3 randomised control trial analysis of the vaccine, which was developed in China, also showed there were no reports of vaccine-related serious adverse events and that most adverse events, including injection-site pain, headache, drowsiness, and general muscle aches, were mild to moderate.

The vaccine, which was developed by CanSino Biologics, Inc. and the Beijing Institute of Biotechnology, is a single-dose viral vector vaccine that can be stored between 2C and 8C. It has been approved for emergency use in 10 countries, including Argentina, Chile, Mexico, and Pakistan, where the phase 3 trial took place.

Study lead author Dr Scott Halperin, from Dalhousie University, Canada, said: "Our study suggests that one dose of Ad5-nCoV is highly effective against severe disease = potentially helping to ease the tremendous strain COVID-19 has put on health systems around the world by keeping people from becoming seriously ill or requiring hospitalisation.

"In addition, because the vaccine is effective against severe disease after one injection, it could help provide improved access to vaccination, especially in low- and middle-income countries, where it can be more challenging to reach people with a two-dose primary vaccination course."

Details of the trial, which is ongoing, are published in today's edition of *The Lancet*.

It began on September 22, 2020, and, by January 15, 2021, had enrolled 36,982 over 18s, of whom 36,727 were randomised to receive either a vaccine or placebo across 66 sites at centres in Argentina, Chile, Mexico, Pakistan and Russia.

The research team carried out an efficacy analysis once the protocol threshold of 150 laboratory-confirmed symptomatic COVID-19 at 28 days post-injection was reached on January 15, 2021. At this point, there were 21,250 trial participants in the primary efficacy cohort.

In the placebo group, there were 105 positive COVID-19 cases out of 10,590 participants and 45 positive COVID-19 cases out of 10,660 participants in the vaccine group. This equates to an efficacy of 57.5% at 28 days post-vaccination.

They team reports efficacy against severe disease was 91.7% at 28 days post-vaccination, which was defined as a minimum of one of clinical signs at rest indicative of severe systemic illness, respiratory failure, evidence of shock, significant acute renal, hepatic, or neurologic dysfunction, or admission to an ICU. There were no COVID-19-related deaths among vaccine recipients.

Ad5-nCoV was found to be well tolerated and produced high levels of anti-RBD antibodies and neutralising antibodies.

However, the authors say that because the efficacy analysis was conducted in samples collected on or before January 15, 2021, they do not know its effectiveness on variants of concern, such as delta and omicron.

Dr Joanne Langley, of Dalhousie University, added: "More research is needed to determine Ad5-nCoV's effectiveness and durability over a longer period of time as well as its effectiveness against variants of concern, including omicron, which is rapidly overtaking delta as the dominant strain worldwide."

Research is now taking place to determine the vaccine's long-term safety and effectiveness as well as its effectiveness against delta, omicron and other variants of concern, while studies are taking place into a potential booster dose.

Halperin SA, Ye L, MacKinnon-Cameron D et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. *The Lancet* 24 December 2021

[abstract]

Tags: Asia | Flu & Viruses | Pharmaceuticals | South America

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES